

Amaranthus Pollen Allergens: Protein Diversity and Impact on Allergy Diagnosis

Syed Mohammed Hasnain, Halima Alsini, Abdulrahman Al-Frayh, Mohamed Osman Gad-El-Rab, Ayodele A. Alaiya

Abstract— Allergenic weeds dominate the pollen air flora (> 80%) of Saudi Arabia. Two species viz *Amaranthus viridis* (*Av*) and *A. lividus* (*Al*) are the most prevalent components. In this study pollen from different *Amaranthus* species were acquired from three sources Greer, Allergon and *Av* & *Al* collected indigenously. To determine IgE mediated sensitization of *Av* and to observe cross-reactivity patterns with other species, an allergological study was conducted using seven *amaranthus* species. Allergenic extracts were prepared in buffered saline. Skin prick test (SPT) was conducted on 132 patients. Protein separation of seven *Amaranthus* species was conducted by SDS-PAGE. The results indicate that the species of *Amaranthus* vary in their protein profiles with a pattern of cross SPT reactivity between the species. However, as the exposure takes place with prevalent pollen form *Av* and *Al*, the commercial extracts using species not present in the region may not be fully relevant to the patients for diagnosis and immunotherapy.

Keywords— Allergy, Diagnosis, Pollen, Protein diversity

I. INTRODUCTION

ALLERGY and asthma in both children and adult can be caused by many allergic pollen grains from weeds, trees and grasses [1]. World allergenic pollen flora varies in their nature and quantity from place to place and fluctuates with geography and climate.

Bronchial Asthma is a very common allergic disease occurring in all age groups, particularly children, all over the world and the trend of asthma prevalence in both developed and developing countries are increasing over the last 30 years [2].

Environmental factors are known to play an important role in the development and elicitation of asthma in genetically predisposed individuals. Although there has also been an increase in the awareness among Allergists /Physicians to

Syed Mohammed Hasnain is with Department of Cell Biology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. (Tel: +966-11-5577681; fax: +966-11-4427858; e-mail: hasnain@kfshrc.edu.sa).

Halima Alsini is with Department of Cell Biology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. (e-mail: halsini@kfshrc.edu.sa).

Abdulrahman Alfrayh is College of Medicine, King Saud University, Riyadh, Saudi Arabia (e-mail: aalfrayh@ksu.edu.sa).

Mohammed Osman Gad-El-Rab is with College of Medicine, King Saud University, Riyadh, Saudi Arabia (e-mail: mogadelrab2007@yahoo.com).

Ayodele A. Alaiya is with Stem Cell & Tissue Engineering Program, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. (e-mail: aalaiya@kfshrc.edu.sa).

diagnose asthma, a combination of various other factors may also be involved in the increased prevalence of asthma [3]. A large number of ornamental plants have been introduced to the kingdom in recent years [4].

The genus *Amaranthus* consist of several species. It is an allergenic weed shedding pollen in the air almost throughout the year in Saudi Arabia with peaks in autumn and spring months. There are a number of *Amaranthus* species in Saudi Arabia as listed in Table I. Each of them, with some synonym, is known by a common name as well. Both, the common and synonymic names are also presented in this table. However, the dominant species on the ground and frequently encountered pollen in the air belongs to *A. viridis* [5] (Fig1).

Because of non-availability, *A. viridis* extract is not included in the diagnostic profile in Saudi Arabia by the clinicians and instead, unrelated imported/commercial extract of other *Amaranthus spp.* With a common name of Pigweeds is included. This is likely to result in false negative reactivity in those patients who are exposed to *A. viridis*. There are only up to 30% cross-reactivity within the weeds pollen allergy but no such cross-reactivity has been documented within all *Amaranthus* pollen allergens [6]. Apart from the cross reactivity, treatment by immunotherapy may not be successful unless precise molecular relation between offending allergen and desensitizing allergens are established.

II. MATERIALS AND METHOD

A. Collection of Indigenous *Amaranthus*

Two *Amaranthus* species (*Av*, *Al*) were primarily collected from Riyadh, Jeddah, Taif and Najran regions. Majority of these species were found growing in parklands, home backyard, home gardens, lawns etc.

Several lots of flowering *Amaranthus* were collected at different time intervals from different places. All collections were properly dried. After drying the collected plants, anthers were separated. The separated anthers were further dried, treated and teased with acetone, centrifuged and dried as raw material, stored at 4°C and used in the preparation of allergen extracts. Pollen samples showing more than 90% purity were included in the investigations.

Pollen for commercial sources

Based on the international availability, commercial pollen grains of the following species were purchased from various commercial suppliers in Europe and USA:

These included: *Amaranthus palmeri*, *Amaranthus tuberculatus*, *Amaranthus retroflexus*, *Amaranthus hybridus* (Greer Laboratory, USA), (*Amaranthus retroflexus*, *Amaranthus tamariscinus*. Allergon Company, Europe).

B. Pollen protein extraction

Both indigenous and commercial pollens were defatted with excess of diethyl ether / n-butanol to achieve maximum removal of lipids and pigments. Antigenic protein was extracted from the defatted pollen with 1:10 weight per volume (w/v) concentration. The extract was prepared in Phosphate Buffered Saline [12] (10 mM PBS pH 8 at 4°C for 72 hrs.). After the extraction, it was centrifuged at 4000 rpm for 15 min and the supernatant was dialyzed (mol. wt. cut limit: 3500) exhaustively against 85 % PBS, lyophilized by freeze drying system in small aliquots and stored at -20 °C and reconstituted, when and as required. Protein content of each extract was determined by Bradford method [13]. The extracts were sterilized by bacterial filtration by passing through 0.45 mm and 0.22 mm filter using Millipore filter units. For *in vivo* SPT, 50% glycerinated extracts were prepared. The purity and sterility for each extract was tested using Brain Heart Infusion Agar and Blood Agar for at least 15 days at 37° C. The test was negative indicating no contamination.

C. Sodium Dodecyl Sulphate Polyacrylamide Electrophoresis (SDS-PAGE)

The procedure outlined by Laemmli [14] was followed. SDS-PAGE was carried out using 12 % polyacrylamide gel using Mini Electrophoretic Apparatus (Bio Rad). Extracts with varying protein concentrations were used in loading. The gels were calibrated with marker proteins with molecular weights of 10, 15, 20, 25, 37, 50, 75, 100, 150, 250 kD (Bio-Rad). The gels were stained using staining solution (10% glacial acetic acid, 0.25 % Commassie brilliant Blue in 45% methanol), then destained for varied periods until protein bands appeared clear. After destaining, the gels were scanned.

D. Skin Prick Test (SPT)

Skin prick tests were performed on 132 allergic patients attending the Allergy clinic at King Khalid University Hospital, Riyadh. Phosphate buffered saline and histamine were also tested as negative and positive control respectively. The skin response was observed after 15-20 minutes of the test and graded as per the criteria:

- < 3mm negative,
- ≥3mm low positive,
- 5-10 mm moderate positive, and
- >10 mm strong positive.

E. Skin Prick Test (SPT)

Out of 132 patients' only seven teen (17) skin test positive patients agreed to give blood samples. Sera was separated by centrifugation and stored at -20°C in small aliquots for further

use. Blood samples from 10 healthy volunteers were also collected and used as control. An approved Research Advice Council (RAC) consent form was signed by each patient for SPT and blood draw.

F. Immunoblot

Electrophoretic transfer of proteins to PVDF membrane following the method of Towbin *et al.* [15] Proteins separated by SDS-PAGE were electrophoretically transferred to a 0.45µm polyvinylidene difluoride (PVDF) membrane for immunodetection of IgE in serum of sensitized subjects bound to allergenic proteins. Highly positive sera from hypersensitive patients were used to determine the IgE binding fractions in pollen extracts.

PVDF membrane (0.45 µm) of the size of the gel was soaked in the transfer buffer, Tris glycine buffer (25mM Tris, 200 mM Glycine, 20% methanol, pH8.3) an hour before the transfer of proteins. Proteins were then blotted to membrane by electrotransfer using the transfer buffer at 30mA at 4°C for overnight.

The un-reacted sights on the membrane were blocked with 5% non-fat milk in 0.05 % Tween20 phosphate buffered saline (PBST) at room temperature for I hour. Washed by PBST then, membrane is incubated with pooled sera of positive individual. Pooled sera from healthy individual showing negative skin reactivity were used as control.

In all incubations, serum was diluted in the ratio of 1:500 using PBS containing 0.05 % Tween20. Membrane was washed thoroughly using 0.05% PBST. After washing, the membrane was blocked by non-fat milk (5%). Membrane was incubated with antihuman IgE peroxidase conjugate (Sigma) in the ratio of 1:10000 in 0.05% PBST for I hour at room temperature. The membrane then washed thoroughly 4 times by washing buffer 0.05% PBST. After the last wash the membrane was washed by PBS to remove all the Tween. Membrane was developed in dark room after ECL super signal incubation for 5 minutes.

III. RESULTS

A. Protein estimation

Electrophoretic transfer of proteins to PVDF membrane following the method of Towbin *et al.* [15] Proteins separated by SDS-PAGE were electrophoretically transferred to a 0.45µm polyvinylidene difluoride (PVDF) membrane for immunodetection of IgE in serum of sensitized subjects bound to allergenic proteins. Highly positive sera from hypersensitive patients were used to determine the IgE binding fractions in pollen extracts.

PVDF membrane (0.45 µm) of the size of the gel was soaked in the transfer buffer, Tris glycine buffer (25mM Tris, 200 mM Glycine, 20% methanol, pH8.3) an hour before the transfer of proteins. Proteins were then blotted to membrane by electrotransfer using the transfer buffer at 30mA at 4°C for overnight.

The un-reacted sights on the membrane were blocked with 5% non-fat milk in 0.05 % Tween20 phosphate buffered saline

(PBST) at room temperature for 1 hour. Washed by PBST then, membrane is incubated with pooled sera of positive individual. Pooled sera from healthy individual showing negative skin reactivity were used as control.

In all incubations, serum was diluted in the ratio of 1:500 using PBS containing 0.05 % Tween20. Membrane was washed thoroughly using 0.05% PBST. After washing, the membrane was blocked by non-fat milk (5%). Membrane was incubated with antihuman IgE peroxidase conjugate (Sigma) in the ratio of 1:10000 in 0.05% PBST for 1 hour at room temperature. The membrane then washed thoroughly 4 times by washing buffer 0.05% PBST. After the last wash the membrane was washed by PBS to remove all the Tween. Membrane was developed in dark room after ECL super signal incubation for 5 minutes.

B. Skin Prick Test (SPT)

Out of one hundred and thirty two (132) consecutive patients attending the Allergy clinic at King Khalid University Hospital, Riyadh (KKUH), sixty five patients (65/47.1%) reacted positively to *Amaranthus* extracts. The skin test reactivity of the 39 patients, who participated in the study are presented in Table II and Fig 3.

In the whole group (39), 31(76.92%) reacted to *A. viridis* (indigenous species), while 26 patients (66.66%) reacted to *A. lividus* (indigenous species).

Twenty five patients (64.10%) reacted to both local extracts. Four patients showed strong reactions to the local *Amaranthus* allergens.

Reactions to the other *Amaranthus* species were as follows: 30(76.92%) to *A. retroflexus* (Allergon), 37(94.87%) to *A. retroflexus* (Greer), 36(92.30%) to *A. tuberculatus* (Greer), 36(92.30%) to *A. hybridus* (Greer) and 37(94.87%) to *A. palmeri* (Greer).

C. Immunoblot

1. Immunoblotting of serum samples (17 patients), we found that 94% of the *Amaranthus* sensitized (IgE mediated positive SPT) individuals have IgE-binding antibodies to *A. viridis* (Indigenous) pollen extract. The major *Amaranthus* allergen defined as binding IgE from most subjects is 52, 31Kda. Other IgE-binding allergens were found at 38, 20, 17and 14Kda. 3.
2. All patients reacted to proteins at 31 Kda and 52 Kda. It was interesting to note that indigenous extracts contained 31 Kda & 52 Kda proteins and out of 17 patients, 16 (94%) reacted to indigenous extract (*A. viridis*). However, one patient who did not react to indigenous (*A. viridis*, possibly an error) reacted to 31 Kda protein of other indigenous (*A. lividus*). Likewise, two patients, who did not react to *A. lividus* (patient no. 6&7), reacted to *A. viridis*. Therefore, it was 100% immune-reactivity towards two species of indigenous *Amaranthus* species (Fig. 4).

Surprisingly, all patients showed allergenicity to sample no.4 (Fig. 5) and 76.47 % showed allergenicity to sample no. 3, species which are not found in KSA.

IV. DISCUSSION

This study has provided much important information as regards to *Amaranthus* allergens that are prevalent in the Kingdom of Saudi Arabia and those which are imported into the country for diagnostic and therapeutic reasons.

There are only a handful of companies in the world, mainly in Europe and North America, producing *Amaranthus* extract for diagnostic and therapeutic use. Most imported extract belong to species which are not found in the Kingdom of Saudi Arabia. The list of commercial Allergenic Pollen Powder (& aqueous extracts) revealed that none of them produce extracts for SPT using *A. viridis*. Our literature search also indicates that there are no commercial suppliers of *A. viridis* pollen powder and extract. This is an interesting observation because *A. viridis* is the dominant species in Saudi Arabia while no suppliers has access to this pollen in the world market to date.

“*Amaranthus* extract” means extract from any species or variety of *Amaranthus* which may or may not include the *viridis* species. Some of the *Amaranthus* are known as: *Amaranthus lividus* (Purple amaranth), *Amaranthus palmeri* (Careless weed), *Amaranthus retroflexus* (Pigweed, Rough (Redroot)), *Amaranthus viridis* (Slender amaranth, Green amaranth) etc.

There may be clinics and hospitals in the Kingdom getting commercial “*Amaranthus* extract”, but the question is that they need to know whether the species they are using is available in Saudi Arabian environment and how prevalent they are? Are patient exposed to the same species where they live??


The results has indicated that there are cross-reactivity between some species of *Amaranthus* and that is the reason that *A. retroflexus*, a species not found in Saudi Arabia, reacted in most patients [16]. The *A. retroflexus* was purchased from Greer company in the United States was highly purified. The allergen extract prepared in our Lab using the same technique, as used for others, gave a high protein content compared to others. However, when the main allergen in our environment is identified, it is questionable to use a cross-reactive allergens [17].

It has been noted (personal communication with many Allergists in the Kingdom) that patients undergoing immunotherapy with “Pollen allergens” are not successfully treated. The probable reason may be the precise molecular relationship to desensitize the patient and the causative allergenic determinants may be different from the determinants in immunotherapy products. In the present study, we found a high degree of reactivity to *Amaranthus viridis* with their IgE binding allergenic proteins at 31 Kda and 52 Kda Fig. 6. Some of the commercial extract also contained the same allergenic proteins [18].

Our study also revealed that though there are a good number of individual who are SPT positive but in immunoblot, even a higher degree of reactivity was recorded.




Fig 1: *Amaranthus viridis* weed




L1: *A. viridis*(indigenous), L2: *A. lividus*(indigenous), L3: *A. retroflukes*(Allergon), L4: *A. retroflukes* (Greer), L5: *A. tbberculatus*(Greer), L6: *A. hybridus*(Greer),L7: *A. palmeri*(Greer),

Fig. 2: 12% SDS-PAGE of different *Amaranthus* Species



L1: *A. viridis*(indigenous), L2: *A. lividus*(indigenous), L3: *A. retroflukes*(Allergon), L4: *A. retroflukes* (Greer), L5: *A. tbberculatus*(Greer), L6: *A. hybridus*(Greer),L7: *A. palmeri*(Greer),

Fig. 3: Mild and Strong SPT reactivities of various *Amaranthus* extracts.



L1: *A. viridis*(indigenous), L2: *A. lividus*(indigenous), L3: *A. retroflukes*(Allergon), L4: *A. retroflukes* (Greer), L5: *A. tbberculatus*(Greer), L6: *A. hybridus*(Greer),L7: *A. palmeri*(Greer)

Fig. 4: Immunoblot showing *Amaranthus* species specific IgE binding fractions of antigenic extracts probed with the sera of SPT positive patient (p13)




Fig. 5: Individual sensitivity patterns to *Amaranthus retroflukes* extract on immunoblotting.




Fig. 6: Immunoblot showing *Amaranthus viridis* specific IgE binding fractions of antigenic extracts when probed with the sera of positive patients (1-9) and control sera (10,11).

TABLE I
AMARANTHUS SPECIES IN SAUDI ARABIA [7-11]

Scientific name	Synonym	Common name
<i>Amaranthus albus</i>	<i>A. var. pubescens</i> , <i>A. graecizans auct. non</i> , <i>A. var. pubescens Uline & Bray</i> [7]	White Pigweed, Prostate Pigweed, Pigweed <i>Amaranth</i> , White <i>Amaranth</i> .
<i>A. caudatus</i>	<i>A. edulis</i> Speg. <i>Amaranthus leucocarpus</i> (S.Watson.), [8]	Pendant <i>Amaranth</i> , Love-lies-Bleeding, Tassel Flower, Quilete.
<i>A. graecizans ssp sylvestris</i>	<i>A. graecizans</i> [9,10] <i>A. blitum</i>	
<i>A. graecizans</i>	<i>A. angustifolius A.albus</i> [9,10]	Prostate Pigweed
<i>A. hybridus ssp hybridus</i>	<i>A. Chlorostachys</i> [10].	Smooth <i>Amaranth</i> , Smooth Pigweed, Red <i>Amaranth</i> , Slim <i>Amaranth</i> .
<i>A. hybridus ssp crutentus</i>	<i>A. crutentus</i> [10].	Purple A., aka, Red A, Mexican grain A, Caterpillar.
<i>Amaranthus palmeri</i>	[11]	Palmer's <i>amaranth</i> , palmer pigweed, careless weed
<i>A. lividus</i> **	<i>A. blitum</i> , <i>A. ascendens</i> [10].	Purple <i>Amaranth</i>
<i>A. spinosus</i>	[9,10]	Spiny <i>Amaranth</i> , Prickly <i>Amaranth</i> , Thomy <i>Amaranth</i> , Spiny <i>Amaranthus</i> .
<i>Amaranthus tricolor</i>	<i>A. tristis</i> , <i>A. mangostanus</i> [10]	Joseph's-coat
<i>A. viridis</i> *	<i>A. gracilis</i> Desf. [8]	Slender <i>Amaranth</i> , Green <i>Amaranth</i>

* Most common in Saudi Arabia (+++) (as per growth pattern)

** Less common in Saudi Arabia (++) (as per growth pattern)

All others species are rare and sporadic.

TABLE II
SKIN TEST REACTIVITY OF 39 PATIENTS TO SEVEN AMARANTHUS EXTRACTS.

ALLERGENS	*(wheal diameter in mm)						
	1 <i>A. viridis</i> (local)	2 <i>A. lividus</i> (local)	3 <i>A. retroflexus</i> (Allergen)	4 <i>A. retroflexus</i> (Greer)	5 <i>A. tuberculatus</i> (Greer)	6 <i>A. hybridus</i> (Greer)	7 <i>A. palmeri</i> (Greer)
Patient No.	*	*	*	*	*	*	*
1	3	4	7	6	6	7	7
2	4	-	-	4	-	-	-
3	8	7	7	5	9	5	8
4	5	5	4	10	6	4	4
5	7	-	8	10	8	7	6
6	4	-	-	7	4	4	4
7	6	7	-	-	-	-	-
8	-	-	4	7	4	4	4
9	-	-	-	4	5	-	6
10	3	3	5	8	10	6	5
11	5	-	6	5	5	6	6
12	7	5	4	8	7	4	7
13	10	10	14	10	10	10	9
14	5	3	8	9	7	6	5
15	4	3	5	7	6	6	5
16	-	-	-	-	4	3	4
17	-	-	3	5	5	5	4
18	5	4	8	15	10	12	8
19	4	4	6	9	6	5	6
20	-	-	-	6	4	4	3
21	5	4	4	4	4	4	4
22	6	6	14	9	9	12	8
23	9	8	5	7	6	5	5
24	4	5	10	6	5	5	7
25	-	-	-	7	5	3	4
26	3	3	3	7	4	6	5
27	4	-	5	3	-	4	6
28	4	4	6	8	6	6	7
29	5	4	7	8	6	5	6
30	3	-	-	5	3	3	3
31	-	4	5	6	8	6	4
32	10	6	4	16	6	3	4
33	7	6	4	8	9	9	9
34	7	5	12	10	14	10	9
35	4	3	5	7	6	6	5
36	4	3	4	7	6	3	4
37	-	-	3	6	5	5	6
38	6	4	-	4	4	5	3
39	7	5	5	4	4	4	4

ACKNOWLEDGMENT

This Research was funded by King Abdul-Aziz City for Science and Technology (KACST) under a Research Grant ARP 27-11. The informed consent form was approved by the Research Advice Council (RAC) of KFSH&RC in Riyadh. The authors also wished to acknowledge Ms. Cheryl Mijares-Oblea for her typographical assistance.

REFERENCES

- [1] B.S. Anand and K. Pawan, "Aeroallergens in clinical practice of allergy in India," *Ann Agric Environ Med*, vol. 10, pp. 131-136, 2003.
- [2] G.W.K. Wong and C.M. Chow, "Childhood Asthma Epidemiology: Insights from Comparative Studies of Rural and Urban Population," *Pediatric Pulmonology*, vol. 43, pp.107-116, 2008.
- [3] M. Moradi-Lakeh, C. El Bcheraoui, F. Daoud, M. Tuffaha, H. Kravitz, M. Al Saeedi, et al, "Prevalence of asthma in Saudi adults: findings from a national household survey. 2013," *BMC Pulm Med*, vol. 15, pp. 77, Jul 28, 2015. doi: 10.1186/s12890-015-0080-5.
- [4] A.R. Al-Frayh, Z. Shakoor, M.O. Gad-el-Rab and S.M. Hasnain, "Increased prevalence of Asthma in Saudi Arabia," *Annals of Allergy, Asthma and Immunology*, vol. 86, pp. 292-96, 2001.
- [5] S.M. Hasnain, A.R. Al Frayh, "Prevalence of Allergenic *Amaranthus viridis* Pollen in seven Different Regions of Saudi Arabia," *Annals of Saudi Medicine*, vol. 27, issue 4, pp. 259-63, 2007.
- [6] R.W. Weber, "Cross-reactivity of pollen allergens: impact on allergen immunotherapy," *Annals of Allergy, Asthma & Immunology*, vol. 99, no. 3, pp. 203-212, 2007.
- [7] United States Department of Agriculture, National Resources Conservation Service. [<http://plants.usda.gov/core/profile?symbol=AMAL>]
- [8] Plants for a future. [<http://www.pfaf.org/user/Plant.aspx?LatinName=Amaranthus+caudatus>].
- [9] A.M. Migahid, "Flora of Saudi Arabia," Riyadh, SA, King Saud University 1996.
- [10] S.A. Chaudhery, "Flora of the Kingdom of Saudi Arabia," Ministry of agriculture & water, National Herbarium, Riyadh, 1999.
- [11] Ministry of Agriculture, Kingdom of Saudi Arabia [<http://www.moa.gov.sa>].
- [12] J.E. Slater, RE EschE, R Lockey, "Preparation and standardization of allergen extracts," *Middleton's allergy principles and practice*, 7th ed., St. Louis: Mosby, 2009, pp 557-608.
- [13] M.M. Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," *Anal Biochem*, vol. 72, pp. 248-254, 1976.U.K. Laemmli, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," *Nature*, vol. 227, pp. 680-685, 1970.
- [14] H. Towbin, T. Staehelin and J. Gordon, "Electrophoretic transfer of proteins from polyacrylamide gel to nitrocellulose sheets," *Biotechnology*, vol. 24, pp. 145-149, 1992.
- [15] M. Villalba, R. Barderas, S. Mas, C. Colás and E. Batanero and R. Rodríguez. "Amaranthaceae pollens: review of an emerging allergy in the Mediterranean area," *J Investing Allergol Clin Immunol*, vol. 24, pp. 371-81, 2014.
- [16] M. Tehrani, M. Sankian, M. Assarehzadegan, R. Falak, F. Jabbari and A. Varasteh, "Immunochemical characterization of *Amaranthus retroflexus* pollen extract: extensive cross-reactive allergenic components among the four species of Amaranthaceae/Chenopodiaceae," *Iran J Allergy Asthma Immunol*, vol. 9, pp. 87-95, 2010.
- [17] A.A. Alaiya, H.A. Alsini, M.O. Gad-El-Rab and S.M. Hasnain, "Protein Profiles of Indigenous and Commercial Extracts of *Amaranthus* Pollen for the Diagnosis of Allergy and Asthma Patients," *World Applied Sciences Journal*, vol. 32, pp. 2354-2361, 2014.